Cel­gene's chemother­a­py Abrax­ane stum­bles in piv­otal pan­cre­at­ic can­cer study

Days af­ter Cel­gene’s Abrax­ane se­cured ap­proval in com­bi­na­tion with Roche’s check­point in­hibitor for front­line use in triple neg­a­tive breast can­cer, the US drug­mak­er re­port­ed that the chemother­a­py failed to im­prove pro­gres­sion-free sur­vival in a piv­otal study in­volv­ing pan­cre­at­ic can­cer pa­tients who had un­der­gone sur­gi­cal re­sec­tion.

Abrax­ane is al­ready ap­proved for use in var­i­ous can­cers: metasta­t­ic breast can­cer, metasta­t­ic non-small cell lung can­cer (NSCLC) as well as metasta­t­ic ade­no­car­ci­no­ma of the pan­creas as first-line treat­ment, in com­bi­na­tion with gem­c­itabine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.